. 2015 Jan 8;308(6):G540–G549. doi: 10.1152/ajpgi.00247.2014

Table 2.

Animal and metabolic characteristics

	LETO		OLETF
	Control	+ l-NAME	Control	+ l-NAME
Serum NO_X, μM	0.33 ± 0.05^a	0.19 ± 0.04^b,c	0.25 ± 0.04^a,b	0.13 ± 0.02^c
Body weight at euthanization, g	419.2 ± 9.8^a	405.3 ± 6.2^a	588.4 ± 12.6^b	557.4 ± 13.6^b
Food consumption during treatment
Absolute, g/wk	159.4 ± 10.9^a	145.8 ± 9.2^a	235.3 ± 9.6^b	186.0 ± 12.2^c
Relative, g·wk⁻¹·g body wt⁻¹	0.38 ± 0.03^a	0.36 ± 0.02^a,b	0.40 ± 0.02^a	0.33 ± 0.02^b
Weight gain during treatment, g	18.8 ± 4.0^a	5.8 ± 3.2^b	34.7 ± 4.0^c	−7.3 ± 8.5^b
DEXA body fat, %	13.5 ± 0.7^a	14.0 ± 0.5^a	27.2 ± 0.8^b	24.6 ± 0.9^c
Epididymal + retroperitoneal fat pad mass, g	6.8 ± 0.3^a	7.4 ± 0.5^a	17.6 ± 2.0^b	17.1 ± 2.2^b
Plasma glucose, mg/dl	186.0 ± 13.7^a	178.1 ± 5.7^a	309.8 ± 23.5^b	312.1 ± 19.7^b
Plasma insulin, ng/ml	8.1 ± 1.2^a	10.1 ± 1.6^a	32.0 ± 3.8^b	22.4 ± 3.1^c
Plasma FFA, mM	0.31 ± 0.03^a	0.32 ± 0.04^a	0.61 ± 0.04^b	0.61 ± 0.03^b
Plasma TAG, mg/dl	40.1 ± 2.4^a	52.9 ± 2.6^a	142.8 ± 10.0^b	162.5 ± 9.0^b

Values are means ± SE (n = 10/group).

LETO, Long-Evans Tokushima Otsuka; OLETF, Otsuka Long-Evans Tokushima fatty; l-NAME, N^ω-nitro-l-arginine methyl ester; NO_x, nitrite + nitrate; DEXA, dual-energy X-ray absorptiometry; FFA, free fatty acid; TAG, triacylglycerol.

Different letter superscripts denote significant differences (P < 0.05). Data have been previously reported (23).